Tag: generative artificial intelligence in drug discovery industry overview

Uncover key drivers, emerging technologies, and competitive movements shaping the generative artificial intelligence (ai) in drug discovery market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Generative Artificial Intelligence (AI) In Drug Discovery Market by the end of 2030?

The market size for generative artificial intelligence (AI) in drug discovery has seen substantial growth recently. It is forecast to increase from $0.25 billion in 2025 to $0.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 30.6%. Historically, this expansion has been driven by factors such as the high costs involved in drug development, developments in computational chemistry, the increasing availability of biological datasets, the adoption of machine learning tools, and investment in pharmaceutical R&D.

The generative artificial intelligence (AI) in drug discovery market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $0.86 billion by 2030, achieving a compound annual growth rate (CAGR) of 27.0%. This expansion during the forecast period can be primarily linked to the incorporation of generative models into development pipelines, the escalating demand for expedited drug discovery, the broader application of biologics optimization, strategic alliances between AI and pharmaceutical companies, and the reduction in time required to bring products to market. Significant developments anticipated during this timeframe encompass the increasing implementation of AI-driven molecule generation, a greater reliance on deep learning in designing drugs, the wider adoption of small molecule discovery applications, the growing integration of AI in lead optimization, and a faster pace in early-stage drug development.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

What Drivers Are Shaping Future Opportunities In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

The increasing volume of clinical trials is anticipated to drive the expansion of generative AI within the drug discovery market. These trials utilize human participants to evaluate the safety and efficacy of novel medical interventions or processes, with the goal of collecting scientific evidence regarding their applicability for human consumption. This growth in clinical trials stems mainly from progress in medical research, a greater prevalence of diseases, evolving regulations, the worldwide expansion of clinical studies, stronger patient advocacy and public awareness, competitive industry pressures, technological innovations, and improved funding avenues. Data from clinical trials powers generative AI models, accelerating drug discovery through the prediction of molecular interactions and the design of new compounds. This collaborative effort facilitates personalized medical approaches, enhances the effectiveness of treatments, leads to better patient results, and fundamentally transforms the pharmaceutical sector. As an illustration, in January 2025, Pharmaceutical Technology, a UK-based business news and media firm, reported that 3,213 trials are scheduled to commence this year, comprising 823 in Phase I and 1,102 in Phase II. Similar to 2024, oncology is projected to maintain its position as the leading therapeutic area, with 946 trials, followed by the central nervous system with 686 trials, and then cardiovascular significantly trailing with 258 trials. Consequently, the increased volume of clinical trials is propelling the expansion of generative AI in the drug discovery market.

Which Segments Are Gaining Traction In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Type: Small Molecule, Large Molecule

2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing

3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction

2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization

What Trends Are Driving The Growth Trajectory Of The Generative Artificial Intelligence (AI) In Drug Discovery Market?

Leading companies in the generative AI drug discovery market are actively developing sophisticated AI-powered tools to accelerate the drug discovery process. These AI-driven instruments speed up drug development by streamlining discovery, design, and clinical trials through the application of predictive analytics and machine learning. They enhance efficiency in areas such as target identification, compound screening, including virtual screening using AI, as well as preclinical development, regulatory compliance, and manufacturing processes. As an illustration, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, introduced two innovative AI-driven solutions. These solutions, the Target and Lead Identification Suite and the Multiomics Suite, are designed to advance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite assists researchers in understanding amino acid functions and predicting protein structures, while the Multiomics Suite expedites the analysis and understanding of genomic data, simplifying the development of personalized treatments.

Who Are The Core Companies Influencing Trends In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Generative Artificial Intelligence (AI) In Drug Discovery Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company

Lab Automation In Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/lab-automation-in-drug-discovery-global-market-report

Artificial Intelligence In Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Future Growth Projections For The Generative Artificial Intelligence (AI) In Drug Discovery Market Size?

Over the past few years, the generative AI market for drug discovery has seen exceptional growth. It is projected to expand from $0.19 billion in 2024 to $0.25 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 30.6%. The historical growth can be linked to various factors including the escalating occurrence of chronic diseases, advancements in drug discoveries and clinical trials, greater integration of AI in healthcare and drug development, expansion of biotech industries, and increased government support.

The market size of generative artificial intelligence (AI) in drug discovery is predicted to witness remarkable growth in the coming years, soaring to $0.7 billion in 2029 with a compound annual growth rate (CAGR) of 28.8%. The projected growth during the forecast period is due to the increase in demand for cost-efficient drug discovery methods, fostering generative AI’s adoption. It’s further influenced by the escalating partnerships between market players, growing computational capacities, the incorporation of generative AI with other rising technologies, and speedy drug development. Emerging trends include incorporating generative AI with experimental biology, high-throughput screenings for expedited drug discovery, the advent of AI-driven platforms for repurposing drugs, and heightened acceptance of cloud-based AI solutions for joint drug discovery efforts.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

Which Demand Drivers Are Strengthening The Generative Artificial Intelligence (AI) In Drug Discovery Market?

The surge in clinical trials is projected to boost generative AI development within the drug discovery industry. Clinical trials, involving human volunteers, evaluate new medical treatments or procedures for safety and efficacy, with the objective to accumulate scientific data regarding their appropriateness for human application. This surge is predominantly linked to progression in medical studies, escalated disease rates, regulatory transformations, globalization of clinical studies, patient advocacy and enlightenment, industry rivalry, technological breakthroughs, and available funding. Data from clinical trials feeds into generative AI models, accelerating drug discovery by forecasting interactions and establishing compounds. This combined approach facilitates personalized medicine, enhances treatment effectiveness, boosts patient results, and transforms the pharma sector. For example, as per ClinicalTrials.gov, a US clinical trial database, by the close of 2023, global registration of clinical trials reached 477,234, a rise from 437,512 trials registered in 2022. Hence, the escalating quantity of clinical trials is propelling the growth of generative AI in the drug discovery market.

What Segmentation Insights Are Provided In The Generative Artificial Intelligence (AI) In Drug Discovery Market Research?

The generative artificial intelligence (AI) in drug discoverymarket covered in this report is segmented –

1) By Type: Small Molecule; Large Molecule

2) By Technology: Deep Learning; Machine Learning; Reinforcement Learning; Molecular Docking; Quantum Computing

3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs); Other End-Users

Subsegments:

1) By Small Molecule: Drug Design And Optimization; Lead Discovery And Identification; Toxicology Prediction; Molecular Property Prediction; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction

2) By Large Molecule: Protein Structure Prediction; Antibody Design; Biologics Optimization; Peptide Design; Biopharmaceutical Discovery And Optimization

Which Notable Trends Are Transforming The Generative Artificial Intelligence (AI) In Drug Discovery Market Outlook?

Leading businesses in the generative AI sector for drug discovery are creating high-tech tools powered by artificial intelligence to fast-track the discovery processes of drugs. These tools, enhanced by AI, hasten the development of drugs by smoothing the process of drug discovery, its design, and clinical trials while using predictive analytics and machine learning. They ultimately improve efficiency in identifying targets and in compound screening, such as AI-based virtual screening, preclinical development, regulatory compliance, and manufacturing procedures. To exemplify, Google Cloud, a cloud computing service from the USA and a branch of Google, launched two groundbreaking solutions driven by AI in May 2023. These solutions – the Target and Lead Identification Suite and the Multiomics Suite – are aimed to advance drug discovery and precision medicine in biotech, pharmaceutical, and public sector entities. The Target and Lead Identification Suite aids researchers in comprehending amino acid roles and forecasting protein structures, while the Multiomics Suite hastens the analysis and comprehension of genomic data, thereby making the creation of personalized treatments simpler.

Which Firms Are Driving Innovation Within The Generative Artificial Intelligence (AI) In Drug Discovery Market?

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Generative Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the generative AI in drug discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2025, By The Business Research Company

Generative Artificial Intelligence Ai In Sports Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-sports-global-market-report

Generative Artificial Intelligence In Development And Operations Devops Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-in-development-and-operations-devops-global-market-report

Artificial Intelligence In Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Generative Artificial Intelligence (AI) In Drug Discovery Market Covering 2025–2034?

The market size for generative artificial intelligence (AI) in drug discovery has witnessed significant expansion in recent years. It is projected to grow from $0.19 billion in 2024 to $0.25 billion in 2025, achieving a compound annual growth rate (CAGR) of 30.6%. This historical growth stems from factors such as the rising prevalence of chronic diseases, advancements in new drug discoveries and clinical trials, initiatives supporting AI integration into healthcare and drug development, the growth of biotech industries, and increasing governmental support.

The market for generative artificial intelligence (AI) in drug discovery is projected to experience substantial expansion in the coming years. This market is anticipated to reach ” $0.7 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 28.8%. Several factors contribute to this growth during the forecast period, including the demand for affordable drug discovery methods, which fuels the adoption of generative AI, an increase in partnerships among market participants, advancements in computational capabilities, the convergence of generative AI with other nascent technologies, and accelerated drug development processes. Key trends anticipated in this period encompass sophisticated technological advancements, the merging of generative AI with experimental biology, the use of high-throughput screening to expedite drug discovery pipelines, the creation of AI-powered platforms for drug repurposing, and a growing embrace of cloud-based AI solutions to facilitate collaborative drug discovery initiatives.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

What Are The Main Drivers Boosting The Generative Artificial Intelligence (AI) In Drug Discovery Industry’s Expansion?

An increase in clinical trials is anticipated to boost the expansion of generative AI in the drug discovery market. These trials enlist human participants to evaluate the safety and efficacy of novel medical interventions or processes, with the goal of collecting scientific information regarding their appropriateness for human application. The growing volume of clinical trials is mainly due to progress in medical research, a higher prevalence of diseases, evolving regulations, the worldwide expansion of clinical research, enhanced patient advocacy and understanding, competitive industry dynamics, technological innovations, and available financial support. Information derived from clinical trials empowers generative AI models, accelerating the drug discovery process through the prediction of molecular interactions and the design of novel compounds. This collaborative effect facilitates personalized medicine, enhances the effectiveness of treatments, leads to better patient results, and transforms the pharmaceutical sector. For example, data from ClinicalTrials.gov, a US-based clinical trial registry, shows that as of the close of 2023, a total of 477,234 clinical trials were registered worldwide, representing a rise from the 437,512 trials recorded in 2022. Consequently, the expanding volume of clinical trials is fueling the development of generative AI in the drug discovery market.

What Are The Leading Segments Analyzed In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

The generative artificial intelligence (AI) in drug discoverymarket covered in this report is segmented –

1) By Type: Small Molecule; Large Molecule

2) By Technology: Deep Learning; Machine Learning; Reinforcement Learning; Molecular Docking; Quantum Computing

3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs); Other End-Users

Subsegments:

1) By Small Molecule: Drug Design And Optimization; Lead Discovery And Identification; Toxicology Prediction; Molecular Property Prediction; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction

2) By Large Molecule: Protein Structure Prediction; Antibody Design; Biologics Optimization; Peptide Design; Biopharmaceutical Discovery And Optimization

What Long-Term Trends Will Shape The Future Growth Of The Generative Artificial Intelligence (AI) In Drug Discovery Industry?

Leading companies engaged in generative AI within the drug discovery market are developing sophisticated AI-powered instruments to expedite drug discovery processes. These AI tools accelerate drug development by optimizing drug discovery, design, and clinical trials through the application of predictive analytics and machine learning. They boost efficiency in areas such as target identification, compound screening (including virtual screening using AI), preclinical development, regulatory compliance, and manufacturing operations. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, launched two innovative AI-driven solutions. These solutions, the Target and Lead Identification Suite and the Multiomics Suite, are designed to enhance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite aids researchers in understanding amino acid functions and predicting protein structures, while the Multiomics Suite accelerates the analysis and comprehension of genomic data, simplifying the development of personalized treatments.

Which Key Market Players Are Investing In Expansion And Innovation Of Generative Artificial Intelligence (AI) In Drug Discovery Market?

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Generative Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the generative AI in drug discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Generative Artificial Intelligence (AI) In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2025, By The Business Research Company

Generative Artificial Intelligence Ai In Sports Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-sports-global-market-report

Generative Artificial Intelligence In Development And Operations Devops Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-in-development-and-operations-devops-global-market-report

Artificial Intelligence In Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Generative Artificial Intelligence (AI) In Drug Discovery Market Expected to Grow Between 2025 And 2029?

The market size for generative artificial intelligence (AI) in drug discovery has seen exceptional growth recently. It is anticipated to expand from $0.19 billion in 2024 to $0.25 billion in 2025, with a compound annual growth rate (CAGR) of 30.6%. The historical growth can be credited to the increasing presence of chronic diseases, new advancements in drug discovery, clinical trials that incorporate AI into healthcare and drug development, the evolution of the biotech industry, and increased support from the government.

Anticipated to observe remarkable expansion in the coming years, the market size for generative artificial intelligence (AI) in the field of drug discovery is set to reach around $0.7 billion in 2029, with a compound annual growth rate (CAGR) of 28.8%. This notable rise during the forecasting time is primarily due to the rising demand for cost-effective drug discovery processes, escalating collaborations between market participants, an increase in computational power, and synergy of generative AI with emerging tech for swift drug development. In addition, the forecast period will witness trends like cutting-edge technology usages, incorporation of generative AI with experimental biology, boosting drug discovery pipelines through high-throughput screening, the emergence of AI-driven platforms for repurposing drugs, and the growing preference for cloud-centric AI solutions in cooperative drug discovery ventures.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Generative Artificial Intelligence (AI) In Drug Discovery Market?

The growth of generative AI in the drug discovery market is expected to be fuelled by an increase in the number of clinical trials. These trials involve human volunteers and are used to evaluate the safety and efficacy of new medical procedures or treatments, with the goal of gathering credible scientific information for their application in humans. Advancements in medical research, an escalated disease burden, regulatory amendments, global clinical research, patient advocacy and awareness, industry competition, technological progress, and availability of funding are all contributing to the increase in clinical trials. The data derived from these trials serves as a crucial input for generative AI models, which accelerates the drug discovery process through predictions of interactions and compound design. This collaboration contributes to personalized medicine, enhances the effectiveness of treatments, betters patient outcomes, and transforms the pharmaceutical field. For example, the US-based clinical trial registry, ClinicalTrials.gov, reported 477,234 registered clinical trials worldwide by the end of 2023, a significant rise from the 437,512 trials registered in 2022. As a result, the expanding number of clinical trials is propelling the growth of generative AI in the drug discovery market.

Which Primary Segments of the Generative Artificial Intelligence (AI) In Drug Discovery Market Are Driving Growth and Industry Transformations?

The generative artificial intelligence (AI) in drug discoverymarket covered in this report is segmented –

1) By Type: Small Molecule; Large Molecule

2) By Technology: Deep Learning; Machine Learning; Reinforcement Learning; Molecular Docking; Quantum Computing

3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs); Other End-Users

Subsegments:

1) By Small Molecule: Drug Design And Optimization; Lead Discovery And Identification; Toxicology Prediction; Molecular Property Prediction; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction

2) By Large Molecule: Protein Structure Prediction; Antibody Design; Biologics Optimization; Peptide Design; Biopharmaceutical Discovery And Optimization

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Generative Artificial Intelligence (AI) In Drug Discovery Market?# Market?

North America was the largest region in the generative AI in drug discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Generative Artificial Intelligence (AI) In Drug Discovery Market?

Leading firms in the generative AI sector for drug discovery are designing superior AI-enabled tools to hasten the drug discovery procedures. The process of drug development is streamlined by these AI-enabled tools, which incorporate predictive analytics and machine learning to expedite drug discovery, design, and clinical trials. They also improve efficiency in areas such as target identification, compound screening through AI-assisted virtual screening, preclinical development, compliance with regulations, and manufacturing procedures. An example of this occurred in May 2023, when Google Cloud, a U.S. cloud computing service from Google, unveiled two novel solutions driven by AI to enhance drug discovery and precision medicine across sectors such as biotech, pharmaceuticals, and the public sector. The Target and Lead Identification Suite aids researchers in decoding the functions of amino acids and predicting protein structures, and the Multiomics Suite accelerates the examination and comprehension of genomic data, resulting in the simplified creation of customized treatments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

What Parameters Are Used to Define the Generative Artificial Intelligence (AI) In Drug Discovery Market?

Generative AI in drug discovery involves using advanced machine learning, especially generative models, to create and identify new pharmaceutical compounds. These AI systems analyze extensive data, including chemical properties, biological activity, and existing drug information to predict and generate novel molecules with potential therapeutic benefits. The primary aim of generative AI in drug discovery is to accelerate the creation and identification of novel pharmaceutical compounds with potential therapeutic effects, optimizing the drug development process by leveraging extensive data to predict and generate new molecules efficiently.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16067

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the generative artificial intelligence (ai) in drug discovery industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Generative Artificial Intelligence (AI) In Drug Discovery Market Through 2034?

The market size for generative artificial intelligence (AI) in drug discovery has seen significant growth in the recent past. The market is estimated to expand from a valuation of $0.19 billion in 2024 to $0.25 billion in 2025, at a compound annual growth rate (CAGR) of 30.9%. Factors contributing to this growth during the historic period include the rising incidence of chronic diseases, advancements in drug discoveries and clinical trials, embrace of AI in healthcare and drug development, the expansion of biotech industries, and growing government support.

The market size of generative artificial intelligence (AI) in the field of drug discovery is predicted to experience substantial growth in the following years. With a compound annual growth rate (CAGR) of 30.6%, it is expected to reach a value of $0.74 billion by 2029. The substantial growth during the forecasted period can be attributed to factors such as the need for cost-effective drug discovery stimulating the adoption of generative AI, an increase in collaborations among market participants, enhanced computational capacity, combination of generative AI with other burgeoning technologies, and accelerated drug development. Key trends projected for the forecast period encompass cutting-edge technologies, the union of generative AI and experimental biology, high-throughput screening for expedited drug discovery pipelines, the creation of AI-based platforms for drug repurposing, and a surge in the adoption of cloud-powered AI solutions for joint drug discovery endeavors.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Generative Artificial Intelligence (AI) In Drug Discovery Market?

The proliferation of clinical trials is projected to drive the expansion of generative AI in the drug discovery industry. Clinical trials, which involve human participants, determine the safety and efficacy of novel medical procedures or treatments with the goal of compiling scientific evidence regarding their appropriateness for human application. The surge in clinical trials is mainly due to strides in medical research, escalating disease prevalence, changes in regulations, the internationalization of clinical research, patient support and awareness, industry rivalry, technological advancements, and funding prospects. The data from clinical trials powers generative AI systems, hastening the drug discovery process by predicting interactions and formulating compounds. This collaboration allows for customized medicine, enhances treatment effectiveness, better patient outcomes, and transforms the pharmaceutical sector. For instance, based on information from ClinicalTrials.gov, a U.S. clinical trial registry, by the end of 2023, a total of 477,234 clinical trials had been registered worldwide, which signifies an uptick from the 437,512 trials that were registered in 2022. Thus, the escalating number of clinical trials is spurring the uptake of generative AI in the drug discovery market.

Which Segments in the Generative Artificial Intelligence (AI) In Drug Discovery Offer the Most Growth?

The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Type: Small Molecule, Large Molecule

2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing

3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction

2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Which Areas Are Leading Regions in the Generative Artificial Intelligence (AI) In Drug Discovery Market Expansion Across the Globe?

North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive the Generative Artificial Intelligence (AI) In Drug Discovery Market’s Growth?

Leading firms in the generative AI drug discovery market are engineering advanced tools powered by AI to expedite drug discovery procedures. AI-empowered tools hasten drug development by optimizing drug discovery, design, and clinical trials with the aid of predictive analytics and machine learning. They enhance productivity in areas like target identification, compound screening, including AI-assisted virtual screening, preclinical development, regulatory compliance, and manufacturing processes. For example, Google Cloud, a well-known cloud computing service from Google based in the US, launched two innovative AI-focused solutions in May 2023. These solutions, known as the Target and Lead Identification Suite and the Multiomics Suite, aim to enhance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite guides researchers in comprehending amino acid functions and predicting protein structures. Meanwhile, the Multiomics Suite expedites the analysis and comprehension of genomic data, making it easier to develop personalized treatments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

What Are the Key Elements That Define the Generative Artificial Intelligence (AI) In Drug Discovery Market?

Generative AI in drug discovery involves using advanced machine learning, especially generative models, to create and identify new pharmaceutical compounds. These AI systems analyze extensive data, including chemical properties, biological activity, and existing drug information to predict and generate novel molecules with potential therapeutic benefits. The primary aim of generative AI in drug discovery is to accelerate the creation and identification of novel pharmaceutical compounds with potential therapeutic effects, optimizing the drug development process by leveraging extensive data to predict and generate new molecules efficiently.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16067

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theGenerative Artificial Intelligence (AI) In Drug Discovery Market?

The increment in clinical trials is believed to accelerate the expansion of generative AI in the drug discovery sector. Clinical trials, which use human participants to examine the safety and efficiency of novel medical procedures or treatments, aim to collect scientific evidence on their appropriateness for human application. The surge in clinical trial numbers is primarily due to progress in medical research, escalation of disease prevalence, regulatory alterations, the international spread of clinical research, patient support and awareness, industry rivalry, technological innovation, and financial support opportunities. The data from clinical trials aids generative AI models, which fast-tracks the discovery of drugs via the prediction of interactions and the design of compounds. This collaboration is instrumental in establishing personalized medicine, enhancing effective treatment, improving patient results, and transforming the pharmaceutical sector. For example, as per ClinicalTrials.gov, an American clinical trial registry, 477,234 clinical trials were registered globally by the terminus of 2023, a rise from the 437,512 trials recorded in 2022. Thus, the surge in clinical trials is pushing the growth of generative AI in the drug discovery sector.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16067&type=smp

#What Growth Opportunities Will Drive the Generative Artificial Intelligence (AI) In Drug Discovery Market’s CAGR Through 2034?

The market size for generative artificial intelligence (AI) used in drug discovery has seen a massive expansion in recent years. The market, valued at $0.19 billion in 2024, is projected to climb to $0.25 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 30.9%. Factors such as the increased prevalence of chronic diseases, progress in drug discovery and clinical trials that involve AI, burgeoning biotech industries, and enhanced government backing are accountable for the growth witnessed in the historic period.

The market size for generative artificial intelligence (AI) in drug discovery is predicted to expand exponentially in the coming years. The market is set to soar to $0.74 billion in 2029, growing at a compound annual growth rate (CAGR) of 30.6%. The anticipated growth during this forecast period is associated with the growing need for affordable drug discovery sparking generative AI adoption, increased partnerships between market players, enhancing computational power, the amalgamation of generative AI with other novel technologies, and swift drug development. The primary trends within the forecast period encompass progressing technologies, the fusion of generative AI with experimental biology, increased use of high-throughput screening to expedite drug discovery processes, the creation of AI-driven platforms for drug repurposing, and a rise in the uptake of cloud-based AI solutions to bolster collaborative drug discovery initiatives.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16067

How Are Consumer Market Innovations Shaping the Current and Future Landscape of theGenerative Artificial Intelligence (AI) In Drug Discovery Market?

Leading firms in the generative AI sector of drug discovery are advancing in the creation of AI-powered instruments that hasten the drug discovery procedures. These AI tools speed up drug creation by making drug discovery, designing, and clinical trials more efficient with the use of predictive analytics and machine learning. This enhances efficiency in areas such as target identification and compound screening, including AI-based virtual screenings, preclinical development, regulatory adherence, and manufacturing processes. For example, in May 2023, Google Cloud (an American cloud computing service by Google) launched two groundbreaking AI-based solutions. These solutions – the Target and Lead Identification Suite and the Multiomics Suite – are aimed at enhancing drug discovery and precision medicine in biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite assists researchers in comprehending amino acid functions and predicting protein structures, while the Multiomics Suite accelerates the understanding and analysis of genomic data, thus simplifying the creation of personalized treatments.

Who Are the Key Market Players Influencing the Growth of the Corn and Generative Artificial Intelligence (AI) In Drug Discovery Industry?

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-drug-discovery-global-market-report

Which Key Market Segments Comprise the Generative Artificial Intelligence (AI) In Drug Discovery Market and Drive Its Revenue Growth?

The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –

1) By Type: Small Molecule, Large Molecule

2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing

3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users

Subsegments:

1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction

2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=16067&type=smp

Which Regions Are Emerging as Leaders in the Generative Artificial Intelligence (AI) In Drug Discovery Market?

North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Generative Artificial Intelligence (AI) In Drug Discovery Market 2025, By The Business Research Company:

Automotive Artificial Intelligence Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/automotive-artificial-intelligence-global-market-report

Generative Artificial Intelligence In Development And Operations (DevOps) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-in-development-and-operations-devops-global-market-report

Artificial Intelligence in Healthcare Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-healthcare-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: